Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, First-In-Human, Multiple Phase, Single and Multiple-Ascending Dose Study of TERN-201 in Healthy Human Participants

Next Previous
X
Search
Trial Profile

A Phase I, First-In-Human, Multiple Phase, Single and Multiple-Ascending Dose Study of TERN-201 in Healthy Human Participants

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jan 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TERN 201 (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Adverse reactions; First in man
  • Sponsors Terns Pharmaceuticals

    • Most Recent Events

    • 14 Oct 2020 According to a Terns Pharmaceuticals media release, abstract from the study has been published in the October supplement of Hepatology, the peer-reviewed journal of AASLD.
    • 14 Oct 2020 According to a Terns Pharmaceuticals media release, data from the study will be presented at The Liver Meeting™ Digital Experience 2020.
    • 29 Aug 2020 Results presented at The International Liver Congress 2020

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top